ReviewGut2005
Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?
Review in Gut, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 43 citations in OpenAlex.
- First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses.The American journal of gastroenterology · 2014Trial
- Characterising the mucosal and systemic immune responses to experimental human hookworm infection.PLoS pathogens · 2012Trial
- Short-term duodenal seal oil administration normalised n-6 to n-3 fatty acid ratio in rectal mucosa and ameliorated bodily pain in patients with inflammatory bowel disease.Lipids in health and disease · 2006Trial
- Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease.APL bioengineering · 2026Article
- Regulation of Intestinal Inflammation by Soybean and Soy-Derived Compounds.Foods (Basel, Switzerland) · 2021Review
- Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies.Journal of inflammation (London, England) · 2020Review
- Yogurt and Cardiometabolic Diseases: A Critical Review of Potential Mechanisms.Advances in nutrition (Bethesda, Md.) · 2017Review
- Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2017Article
- Intrarectal administration of mCRAMP-encoding plasmid reverses exacerbated colitis in Cnlp(-/-) mice.Gene therapy · 2013Article
- Helminthic therapy: improving mucosal barrier function.Trends in parasitology · 2012Review
- Bio-physical characteristics of gastrointestinal mucosa of celiac patients: comparison with control subjects and effect of gluten free diet-.BMC gastroenterology · 2011Article
- Muc17 protects intestinal epithelial cells from enteroinvasive E. coli infection by promoting epithelial barrier integrity.American journal of physiology. Gastrointestinal and liver physiology · 2011Article
- Human intestinal MUC17 mucin augments intestinal cell restitution and enhances healing of experimental colitis.The international journal of biochemistry & cell biology · 2010Article
- Article
- What is the origin of ulcerative colitis? Still more questions than answers.Postgraduate medical journal · 2006Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luminal delivery of phosphatidyl rich phospholipids appears to reduce mucosal inflammatory activity in a high proportion of patients with chronically active ulcerative colitis. The simplicity and apparent safety of this therapeutic approach offers new insights into the importance of the mucus barrier in the pathogenesis and treatment of ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.